Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Get the latest Nuvalent, Inc. (NUVL) stock news and headlines to help you in your trading and investing decisions.

Taletrectinib is a ROS1 inhibitor in a pair of pivotal phase 2 trials in patients with ROS1-positive non-small cell lung cancer (NSCLC) – TRUST-1 and TRUST-2 – with results due next year.

Its based on both the image_tools cam2image demos for ROS2 as well as the libuvc and usb_cam project for ROS1. Features CameraInfo available CompressedImage topic (see compressed images for ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) ...